Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?
Trends Pharmacol Sci, 1997/5;18(5):164-71.
Teixeira MM[1], Gristwood RW, Cooper N, Hellewell PG
Affiliations
PMID: 9184477
Impact factor: 17.638
Abstract
Phosphodiesterase type 4 (PDE4) plays a major role in modulating the activity of virtually all cells involved in the inflammatory process. Inhibitors of this enzyme family display impressive anti-inflammatory and disease-modifying effects in a variety of experimental models. In this review, Mauro Teixeira, Robert Gristwood, Nicola Cooper and Paul Hellewell examine the capacity of PDE4 inhibitors to exert anti-inflammatory actions in vivo and discuss the potential of this class of drugs to take their place as novel therapeutic agents for a variety of inflammatory diseases.
MeSH terms
3',5'-Cyclic-AMP Phosphodiesterases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclic Nucleotide Phosphodiesterases, Type 4; Humans; Isoenzymes; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases
More resources
EndNote: Download